Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.

Dreucean, Diane; Nguyen, Steffany N; Donahue, Kevin R; Salazar, Eric; Ruegger, Melanie C

Dreucean, Diane; Nguyen, Steffany N; Donahue, Kevin R; Salazar, Eric; Ruegger, Melanie C.

Afiliação

Dreucean D; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA. ddreucean@houstonmethodist.org.
Nguyen SN; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.
Donahue KR; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.
Salazar E; Department of Pathology and Genomic Medicine - Houston Methodist Hospital, 6565 Fannin St, Houston, TX, 77030, USA.
Ruegger MC; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.

J Thromb Thrombolysis ; 52(1): 161-169, 2021 Jul.

Article em En | MEDLINE | ID: mdl-33099722

Assuntos

Inibidores do Fator Xa/uso terapêutico; Pirazóis/uso terapêutico; Piridonas/uso terapêutico; Rivaroxabana; Tromboembolia Venosa; Anticoagulantes; Humanos; Piridonas/efeitos adversos; Estudos Retrospectivos; Rivaroxabana/uso terapêutico; Tromboembolia Venosa/tratamento farmacológico

Palavras-chave

Anti-Xa; Apixaban; Direct oral anticoagulant; Rivaroxaban; Thrombosis; Treatment failure

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Piridonas / Tromboembolia Venosa / Inibidores do Fator Xa / Rivaroxabana Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google